The Board

Advisory Board

The Board

The Academy is Governed by a Board of Directors, the board is comprised of members who are elected by the membership and give their time and expertise free of charge.

The Board

Prof Jamshed Anwar
I have a degree in Pharmacy, a PhD in Chemical Physics/Crystallography from Birkbeck College London, University of London, and have read advanced modules in Mathematics with the Open University. Prior to my appointment at Lancaster, I held a Chair in Computational Pharmaceutical Sciences at the Institute of Life Sciences Research (formerly the Institute of Pharmaceutical Innovation), University of Bradford, where I also held the position of Director of Research for the School of Pharmacy. Previous to that I was a Reader in the Molecular Biophysics group at King's College London. I have also spent periods at the University of Pennsylvania, the Institute of Atomic & Molecular Physics (AMOLF) in the Netherlands, and the University Chemical Laboratory, Cambridge. Before joining academia I had short career in the pharmaceutical industry with GSK where I developed the oral delivery system for the antibiotic Cefuroxime Axetil (Zinnat), which before its patent expiry earned GSK �500m/year. This delivery system was probably the first successful use of the amorphous form of a drug to enhance efficacy.

Ms Helen Barker
Helen is the managing director of Project-ion Ltd. and program manager in infectious diseases at the University of Oxford. She is an experienced project director in the strategic and technical development of a broad portfolio of R&D; programs. Helen joined the APS in 2001 and the New Scientists Focus Group shortly after. Elected on to the board in 2008, she was appointed APS Chief Scientist in 2012. Graduating from the University of Sunderland in Chemical and Pharmaceutical Science, Helen worked for Bristol-Myers Squibb, primarily developing analytical methods for API and drug product. Subsequently gaining over 15 years of experience working for Pfizer, Helen developed a range of solid, liquid and inhaled programs. Broadening experience across the Pharmaceutical Sciences and R&D;, through successful delivery of projects and initiatives, Helen developed innovative strategies and led global multidisciplinary program teams, both in CMC and pan-R&D.; Therapeutic areas of key experience include infectious and respiratory diseases. Research areas include modernizing medical microbiology with genetics, reactions in the solid state, predictive models and intelligent software. Core interests include development of novel healthcare concepts, business and program development, supporting emerging Pharmaceutical Scientists and engaging key opinion leaders.

Dr Geoff Davison
Geoff is CEO of Bionow the membership organisation for life science businesses in the North of England. Prior to this Geoff was founder and Technical Director of Biorite Ltd and Advanced Biomedical Ltd both spin-out companies from the University of Manchester. Geoff has a degree in Biochemistry and a PhD from the School of Pharmacy, University of Manchester where he began his career undertaking postdoctoral research.

Prof Bill Dawson
Bill Dawson retired from Eli Lilly and Co in 1996 after 27 years service and established Bionet Ltd as a health care consultancy working at the interface between academia and industry. At Lilly, Bill was Research Director for 14 years and took 15 compounds into development, two of which reached the market. Latterly, he was Director of Technology Acquisition, Europe, for Lilly. He continues to be a member of the ABPI Academic Liaison Working Group. He is Director of the University of Manchester Medicines Network. He is a non-executive director of Proteome Sciences plc, Antitope Ltd, Pharmovation Ltd and a member of a number of corporate Scientific Advisory Boards. Previously, he was a Director of Biovation Ltd, purchased by Merck KGaA, Enzacta Ltd, merged to form Enact Pharma Ltd and now part of Protherics plc and the Babraham Institute where he served the maximum two terms. He was a Board Member of the Pharmaceutical Licensing Group from 1994-2005. PLG is the professional organisation representing the majority of licensing executives in the UK. He has been active in peer review for MRC, EPSRC and BBSRC and has participated in a number of DTI grant and review panels. He is a Visiting Professor in the School of Science and Mathematics at Sheffield Hallam University and is a Governor of the University of Brighton and of De Montfort University. He is a Fellow of the School and was previously a member of staff in the pharmacology department having completed his PhD at the School under Professor Geoffrey B West Professor Dawson qualified as a pharmacist and specialised in pharmacology. His research interests are in immunopharmacology and in the rational design, selection and progression of new medicines through optimal research and development programmes.

Dr Dennis Douroumis
Dr. Douroumis obtained his Diploma in Chemistry and PhD from the Department of Pharmacy at Patras University in Greece. He studied the development of electroanalytical techniques for in situ monitoring of drug release from liposomal formulations. He worked as a postdoc fellow (2004) at the Friedrich�Schiller University of Jena, Department of Pharmacy with Professor Alfred Fahr. He studied the development of parenteral formulations of antiepileptic drugs (post funded by Novartis Pharma, Basel). After the completion of this project he worked as a Team Leader (2005) again with Professor Fahr in the development of nano � liposomal formulations and treatment of Rheumatoid Arthritis by applying Photodynamic Therapy (post funded by Biolitec Pharma GmbH). Following this, he worked for Phoqus Pharmaceutical plc as a Senior Scientist (2005) at the Product Development Department. His main tasks were the development of sustained/pulsatile release formulations, fast disintegrating dosage forms (FDDF) and taste masking of bitter drugs, also focussing on the development of coated coronary stents (Cypher) using a novel electrostatic dry powder deposition technology (EDPDT). Dr. Douroumis joined the School of Sciences at Greenwich University in November 2007, gaining a Postgraduate Certificate in Higher Education (PGCert), from the School of Education, University of Greenwich in 2008. He is a member of the Journal of Nanomedicine and Nanoscience (JNMNT), Omics Publishing Group Editorial Board, and a member of the following Societies: �The Higher Education academy (UK) �Academy of Pharmaceutical Sciences (APS � UK) �Phospholipid Research Centre (Lipoid, Germany) �Greek Chemists Association (Greece)

Dr Sarah Eccleston
Dr. Sarah Eccleston is Head of Technical Development at Aptuit�s Glasgow site. The site specializes in the development and manufacture of sterile liquid and lyophilized products. Dr. Eccleston�s previous experience includes work in both the industrial and academic sectors. She graduated with a Masters Degree in Pharmacy (Strathclyde University, UK), and after a period of working in the formulation development department at Quintiles, she completed her Doctorate in Pharmaceutical Chemistry at the University of Manchester. Her thesis involved the design and development of novel hydrogel nanoparticles for drug delivery applications. Dr. Eccleston returned to Strathclyde University where she was a postdoctoral research scientist. The scope of her work included the development of novel chronotherapeutic oral dosage forms and was subsequently focused on patenting, licensing and commercialization of the drug products. She returned to the pharmaceutical industry as a senior formulation development scientist at a small CRO/CMO, specializing in the development and manufacture of liquid filled capsules. In the latter part of 2012, she joined Aptuit�s Glasgow site, assuming her current role. Dr. Eccleston is a member of the Board of Directors of the Academy of Pharmaceutical Scientists (the professional body representing pharmaceutical scientists within the UK) and sits on the UKPharmSci conference organizing committee. Additionally, she is a member of the Controlled Release Society�s (CRS) leadership team and a member of the CRS annual meeting programming committee.

Dr Shaun Fitzpatrick
Shaun Fitzpatrick is a senior research fellow at Development Laboratories, Merck Sharp & Dohme Research Laboratories, Hertford Road, Hoddesdon

Dr Michael Gamlen
Michael has been working with pharmaceutical tablets for almost 40 years. He studied Pharmacy, specialising in Pharmaceutical Engineering, at Sunderland Polytechnic from 1973-76. After a short spell at the Boots Company Ltd in Nottingham, he studied for PhD with Professor Mike Newton at Nottingham University. He joined Beechams Pharmaceuticals in 1980 to work on the Beechams instrumented rotary tablet press with Peter Ridgway Watt, leaving to join the Wellcome Foundation Ltd in 1981 with Trevor Jones. As Head of Solid Dosage Form at Wellcome, he managed the development of their wide range of oral solid dosage products in the 1980s and 90s including acrivastine, acyclovir, zidovudine, atovaquone and lamotrigine. He was also responsible for managing the Wellcome compaction simulator from 1990-1995 including making it available as a �general use� machine. He left Wellcome to join Vanguard Medica Ltd (now Vernalis) in 1996, and entered the world of consultancy in 2000 as the Managing Director of Pharmacetical Development Services Ltd. He started working on the Gamlen Tablet Press in the 2005, and has been offering a materials testing services for the pharma industry ever since. He founded Gamlen Tableting Ltd in January 2011 and has been working to explore and develop the GTP-1 ever since. He is an APS Board member.

Dr Francesca Greco
Francesca Greco is an Associate Professor in Drug Delivery at the Reading School of Pharmacy and sits on the board of directors of the Academy of Pharmaceutical Sciences. She graduated from Pisa University with an MPharm (110/110 cum laude), which included a one-year research project at Pharmacia (now part of Pfizer) in Nerviano, Milan (Italy). She then undertook a PhD in drug delivery under the supervision of Prof. Ruth Duncan and Prof. Rob Nicholson, in Pharmacy, Cardiff University (awarded in March 2006). Immediately after completion of her PhD, Francesca was appointed to a lectureship at the Reading School of Pharmacy (July 2006) and she was then promoted to Associate Professor in May 2012. Her research in polymer-drug conjugates led to several publications in peer-reviewed journals and her work has been presented at national and international conferences. Francesca was awarded prizes for her research, including an invitation to the �Roche Symposium for leading scientists of the next decade� (Basel, Switzerland, 2007). Francesca acts as referee for scientific journals including the Journal of Controlled Release, Molecular Pharmaceutics and the Journal of Biomaterials Applications and for funding bodies, including EPSRC. Francesca leads an interdisciplinary research group currently constituted by 4 PhD students.

Prof Michael Heinrich
Head of Centre, Centre for Pharmacognosy and Phytotherapy, The School of Pharmacy, Univ. London (since 1999). Pharmacognosist, biologist (Dr. rer nat.habil, Univ. Freiburg 1989, 1997, Dipl. Biol, 1985) and anthropologist (M.A., Wayne State Univ, 1982), with a many years of research experience in a multitude of aspects of medicinal and food plant research (esp. bioactive natural products), as well as at the interface of cultural and natural sciences Research interest: � Biological pharmacy (bioactive natural products / pharmacognosy / phytotherapy): Anti-inflammatory and anti-oxidant natural products, the transcription factor NF-B and its pathway as molecular targets of natural product research, metabolomic approaches in drug discovery, quality and safety of herbal medical products, effects of HMPs on the Cytochrome P450 system � Medicine and Food Use: Use of herbal medicines in migrant communities in London, history of medicinal plant use in Europe, food and medicinal plant usage in the Mediterranean, pharmaceutical ethnobotany of Mexican indigenous groups, medical anthropology of Mexican indigenous groups (Mixe and others). Other: Editor in Chief Frontiers in Ethnopharmacology, Reviews� Editor � Journal of Ethnopharmacology, Section Editor Phytochemistry Letters, associate editor Journal of Pharmacy and Pharmacolology.

Dr Kevin King
Kevin King is Senior Director of Formulation & Process Development in Biotherapeutics Pharmaceutical Sciences at Pfizer. He is a biochemist and a graduate of the University of Wales, UK and has more than 17 years experience in the development of biotherapeutics. He has worked previously at Hoffmann-La Roche, Procter & Gamble and Lonza Biologics. As Senior Director of Formulation & Process Development he leads a group of pharmaceutical scientists involved in investigating biotherapeutic formulation stabilization technologies, formulation development, delivery technologies and applying the learnings in the formulation design of Pfizer�s biotherapeutic portfolio.

Dr Majella Lane
Dr Majella Lane was educated in Trinity College, Dublin where she obtained her BSc (Pharmacy) and PhD degrees. She has previously held academic posts in Trinity College, Dublin and is a Visiting Scientist at the College of Pharmaceutical Sciences, University of Michigan. To date she has been involved in the supervision of 10 PhD students. Major collaborators include Professor Jonathan Hadgraft, Professor Sergei Kazarian (Imperial College, London), Professor Jeanetta du Plessis (North West University, South Africa) Dr Roy Dalmo (Department of Marine Biotechnology, University of Tromso), Professor Brian Adair (Department of Veterinary Science, Queen�s University of Belfast). Dr Lane and Professor Hadgraft host a number of visiting scientists from their collaborator institutes and also host visiting industrial scientists who wish to develop expertise in their laboratories. Dr Lane acts as a consultant to a number of pharmaceutical companies and to date has acted as reviewer for the following pharmaceutical science journals: International Journal of Pharmaceutics, Journal of Pharmaceutical Sciences, European Journal of Pharmaceutics and Biopharmaceutics, Journal of Pharmacy and Pharmacology, Critical Reviews in Therapeutic Drug Carrier Systems, Journal of Drug Targeting, Molecular Pharmaceutics, and Expert Opinion on Drug Metabolism and Toxicology. Dr Lane is the Secretary of Skin Forum, an organisation which represents scientists from a diverse range of disciplines who share a common interest in the physicochemical and biological properties of human skin. The Forum originally evolved from an EPSRC Life Sciences Interface Network.

Prof Jayne Lawrence
Jayne is Professor and Head of the Pharmaceutical Biophysics Group. She is currently on a 50% secondment at the Royal Pharmaceutical Society (RPS) as their Chief Scientist. At the RPS Jayne is responsible for science and research, performing a variety of roles including working with other scientific organisations and the media and ensuring that the RPS and its membership is up to date with the latest scientific developments in pharmacy. This is a role she has performed since 2007. At King�s, Jayne�s research has focussed on improving the delivery of low molecular weight drugs and biomolecules such as DNA and siRNA using a range of novel and conventional surfactant/polymer and lipid molecules. Jayne is particularly interested in understanding how the structure of a molecule influences the molecular architecture of the delivery vehicle it forms and its fate in the target cell. To achieve these aims Jayne uses a range of advanced analytical techniques including light and neutron scattering and reflectivity. Jayne sits on a number of national committees including the Academy of Pharmaceutical Sciences (Vice-Chair), the United Kingdom and Ireland Controlled Release Society (Treasurer) and the Joint Pharmaceutical Analysis Group, the Institute of Physics and Royal Society of Chemistry�s Joint Neutron Group. She has recently been appointed Vice-Chair of the Formulation and Pharmaceutical Technology Special Interest Group for the International Pharmaceutical Federation. Jayne is a pharmacist, having completed a BSc in Pharmacy at Liverpool Polytechnic and undertaken a year�s pre-registration training in community and industrial pharmacy. After qualifying as a pharmacist Jayne undertook a PhD at Manchester University under the supervision of Professors Peter Elworthy and David Attwood. Jayne started her academic career as a lecturer in Pharmacy at Chelsea College, which subsequently merged with King�s College. Jayne has spent sabbaticals working in the pharmaceutical industry and retains excellent links with the industry.

Dr Claire Martin
Claire completed her PhD in pharmaceutical science at The School of Pharmacy, University of London and subsequently undertook a BBSRC-funded postdoctoral fellowship at The School of Pharmacy. Claire joined the University of Wolverhampton in April 2006 and is a Senior Lecturer in Pharmaceutics. Her current research interests include: � Environmentally responsive controlled release delivery systems for wound management � Formulation development of novel antimicrobial agents � In vitro modelling of wound healing

Dr Mark McAllister
Dr Mark McAllister is a team leader in the Research Formulation group of Pfizer, PGRD, in Sandwich, UK. He graduated in Pharmacy from Queens University Belfast in 1990 and completed an industrial/hospital pre-registation year before commencing a PhD programme (development of liposomal polymyxin for the treatment of cystic fibrosis) at Aston University with Prof. Oya Alpar. His first industrial appointment at Hoechst-Roussel, Swindon, provided experience working with silicone-based hormone sustained-release. Mark moved to SmithKline Beecham in 1995 where he gained experience in drug absorption profiling, biopharmaceutics and early phase candidate assessment. As a manager within the Strategic Technologies department of GlaxoSmithKline Pharmaceutical Development in Harlow, he was responsible for a number of technology development programmes spanning areas such as oral modified-release and bioenhancement. Since joining Pfizer in 2008, he has continued his research interests in biopharmaceutics and provides formulation support for programmes from early discovery through to proof-of-concept stage.

Dr Carol O'Connor
Carol has over 20 years drug development, managerial and project management experience working in the biotechnology, pharmaceutical and device industries. She is a registered Pharmacist with a PhD from the University of Manchester, in controlled drug release Her background is in pharmaceutical development and CMC regulatory affairs with scientific and technical knowledge in drug delivery combined with business and commercial skills. This she has gained from a career working for initially Fisons and then Astra Zeneca in Pharmaceutical development and project management. Moving into Programme Management with Quadrant Healthcare working with novel particle technologies and biologicals, with a range of partnering companies. She is currently a consultant, involved in a range of projects at all stages of drug development, for in house development and partnering from small start-up companies to multinational companies.

Prof Yvonne Perrie
Professor Yvonne Perrie is the Chair in Drug Delivery within Aston Pharmacy School, Aston University, Birmingham, UK. She has a BSc in Pharmacy (1994) from Strathclyde University and is registered with the General Pharmaceutical Council. In 1998 Yvonne received her PhD from the University of London where she investigated the use of liposomes for gene delivery under the supervision of Professor Gregory Gregoriadis. After working for a newly established Drug Delivery Company, Lipoxen Ltd, Yvonne joined Aston University in 2000 and since 2007 holds the Chair in Drug Delivery. Yvonne�s research is focused on the development of particulate carrier systems to facilitate the delivery of drugs and vaccines and aims to provide practical solutions to current healthcare problems. Yvonne is currently a Director-at-Large for the Controlled Release Society is also Editor in Chief of both the Journal of Liposome Research and Pharmaceutics. In addition Yvonne is an Associate Editor for the Journal of Drug Targeting and the Journal of Pharmacy and Pharmacology. Yvonne is currently the Head of Pharmacy within the School of Life and Health Science.

Mr Alan Ramsay
Alan is the Company Secretary for the APS and is a Director of AssociAction Enterprises - the APS Secretartiat. Alan has over 25 years experience in developing and implementing management and administration systems and is a specialist in delivering professional conferences for associations.

Dr Richard Storey
Richard�s background is primarily in solid-state and materials science. He has worked in both early and late stage development since he joined AstraZeneca in 2003. His current role is in the area of process understanding and the identification of critical quality attributes for formulation. Previously Richard has been heavily involved in salt and polymorph selection in his current role and in Pfizer. Richard has experience in a wide range of physical analytical techniques as well as automation from both industrial environments and during his academic studies to PhD in the area of crystallisation. Richard is currently the treasurer and a board member of the APS.

Dr James Tang
James Tang is currently Reader in Pharmaceutics and FP7-IRSES HEPTAG EXCHANGE Program Coordinator at University of Wolverhampton. After his degree studies in Physical Chemistry, Pharmaceutical Chemistry, and Biomaterials, James has teaching experience at undergraduate and postgraduate levels in China and United Kingdom, leading to his qualification of learning and teaching in high education and Fellowship at the Higher Education Academy, UK. His research activities include: biomaterials and artificial internal organs, controlled release, polymer synthesis and processing, scaffold biomaterials and tissue regeneration, and micro- and nano-particle engineering, leading to disease based targeted delivery for diagnosis and treatment, with the supports of the National Natural Science Foundation of China (NSFC); Agency for Science, Technology and Research (A*STAR), Singapore; UK Research Councils (EPSRC, BBSRC, MRC); European Commission 6th and 7th Framework Programme; and Technology Strategy Board UK. James is not only trained in academic research but also in executive management. Actively engaging local communities and academic societies, James has served as Journal Editor of Journal of Biomedical Engineering (ShenWu Yi Xue Gongcheng Xue Zhazhi), Society of Biomedical Engineering, China; Editorial Board Member for Nanoscience and Nanotechnology Letters; Honorary Senior Lecturer, Keele University, UK. James is also Guest Professor, Sichuan University, China, linking to UK China collaboration within the Academy.

Dr Claire Thompson
From a degree in Biochemistry at University of St. Andrews, Claire moved into the pharmaceutical arena via a PhD at School of Pharmacy, University of Nottingham under Professor Clive Roberts. Claire then progressed into industry through a post-doctoral position at Pfizer Global R&D;, Sandwich. It was here that she developed her expertise in assessing the physical attributes of drug substance intended for inhaled formulations. In 2005, Claire joined GlaxoSmithKline as Senior Scientist supporting the physical property characterisation of API during development. She then progressed to Principal Scientist, leading the physical property determination of drug products and heading a global Technical Expert Team. In Oct 2009, Claire joined Molecular Profiles as Associate Director of Preformulation. Here, her role involved the development of new service areas and managing the delivery of Preformulation projects for Virtual, Biotech and Pharmaceutical Clients. In Mar 2011, Claire became Director of Pharmaceutical Development with Oxford Nutrascience, a Virtual Pharmaceutical company using pharmaceutics and drug delivery science to develop advanced medicines, adding value to generic and soon to be off patent APIs.

Dr John Wahlich
John is a consultant in the pharmaceutical sciences with over 30 years� experience in product development. John is a chemist by training (PhD from Nottingham School of Pharmacy) and has analytical and formulation expertise gained from leadership roles in product line extensions, physical properties and early stage development in GlaxoSmithKline